TITLE

MEDIGENE AG SUBMITS ELIGARD MAA TO GERMAN REGULATORY AGENCY

PUB. DATE
June 2002
SOURCE
Worldwide Biotech;Jun2002, Vol. 14 Issue 6, p8
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports that MediGene AG has submitted a Marketing Authorization Application for Eligard� 22.5 mg leuprolide acetate for the treatment of advanced prostate cancer, to the German regulatory authority, Bundesinstitut fur Arzneimittel und Medizinprodukte.
ACCESSION #
6772525

 

Related Articles

  • Eligard receives marketing authorization in Germany.  // PharmaWatch: Cancer;January 2004, Vol. 3 Issue 1, p18 

    Reports on the marketing authorization received by MediGene AG for the prostate cancer drug, Eligard in Germany. Terms of the marketing agreement between MediGene and Atrix; Treatment functions of Eligard.

  • MediGene's RhuDex on Hold After Death of Trial Volunteer. Sheridan, Cormac // BioWorld International;7/9/2008, Vol. 13 Issue 28, p4 

    The article describes the case of 48-year-old Peter Munro who suffered cardiac problems and died some days after receiving a scheduled dose of Rhudex, an experimental rheumatoid arthritis drug manufactured by MediGene AG. He was a study participant at Charles River Laboratories Inc. along with...

  • MediGene awaits approval of key cancer treatment.  // PharmaWatch: Cancer;October 2003, Vol. 2 Issue 10, p14 

    Reports that MediGene is said to be awaiting the approval of its prostate cancer drug Leuprogel. Plans to launch the drug before the year-end; Share price for MediGene; United States Food and Drug's approval of Atrix Laboratories.

  • RhuDex on Hold After One Death in Trial.  // Bioworld Week;7/14/2008, Vol. 16 Issue 28, p3 

    The article reports that Martinsried, Germany-based MediGene AG has put a hold on a trial of its experimental RhuDex, a rheumatoid arthritis drug, following the death of one of the study participants. Defending the issue, the company asserts that the death of the participant at Charles River...

  • MediGene Spins Out Oncolytic Virus Assets to Start-up Catherex. Sheridan, Cormac // BioWorld International;4/14/2010, Vol. 15 Issue 15, p1 

    The article reports on the sale of the oncolytic herpes simplex virus (oHSV) portfolio of MediGene AG to startup Catherex Inc. Under the deal, MediGene will acquire a 40% stake in Catherex in exchange for the portfolio. According to Catherex President and Chief Executive Officer (CEO) Mike...

  • OTHER NEWS TO NOTE.  // BioWorld Today;5/21/2009, Vol. 20 Issue 97, p2 

    This section offers news briefs on the biotechnology industries. A drug discovery agreement between Argenta Discovery Ltd. and Genentech Inc. has been extended for two years. A 50.1 percent interest in Arana Therapeutics Limited's shares was acquired by Cephalon International Holdings Inc., a...

  • MediGene mTCR Platform Becomes Immunocore Ltd. Hollingsworth, Catherine // BioWorld Today;10/2/2008, Vol. 19 Issue 192, p2 

    The article reports that MediGene AG and three private investors have founded Immunocore Ltd., an independent company that will take over MediGene's technology platform for monoclonal T-cell receptors (mTCR). Immunocore will be merged with, and take over the employees of the subsidiary MediGene...

  • New Data Help PhytoCeutica Push Botanical Drug Pathway Push Botanical Drug Pathway. Morrison, Trista // BioWorld Insight;8/23/2010, Vol. 18 Issue 34, p2 

    The article reports on the preclinical data published by PhytoCeutica that will be of help in turning the botanical drug PHY906, a formulation of the traditional Chinese herbal mixture called Huang Qin Tang, into a Food and Drug Administration (FDA)-approved drug in the U.S. It notes that plenty...

  • MediGene's RhuDex on Hold After Death of Trial Volunteer. Sheridan, Cormac // BioWorld Today;7/9/2008, Vol. 19 Issue 132, p2 

    The article reports on the decision of MediGene AG to stop the Phase 1 trial of RhuDex after a volunteer died at Charles River Laboratories Inc. The reason behind the death of 48-year-old Peter Munro is still not defined as due to the medication or to other factors. The participant experienced...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics